SuperworthcbdMD YCBD
- Market cap
- $4.1M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $20.9M
- +10% on a year ago
- Net margin
- −13.8%
- Free cash flow yield
- −59.3%
cbdMD trades at 0.2× sales. Revenue was $20.9M over the last twelve months, up 10% on a year earlier with a −14% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.7M−27% | $5.4M−12% | $4.4M−30% | $5.2M−16% | $4.6M−20% | $5.1M−5% | $4.7M+9% | $4.6M−11% | $4.7M+4% | $5M−2% | $5.6M+19% | $5.6M+21% | |
| Cost of revenue | $2.2M−25% | $1.8M−28% | $1.8M−19% | $1.8M−22% | $2.1M−3% | $1.7M−6% | $1.8M−0% | $1.8M+0% | $1.9M−8% | $2M+18% | $2.4M+33% | $2.5M+42% |
| Gross profit | $3.5M−29% | $3.6M−0% | $2.6M−36% | $3.4M−12% | $2.5M−31% | $3.4M−4% | $3M+15% | $2.8M−17% | $2.8M+13% | $3M−12% | $3.3M+10% | $3M+7% |
| −$15.2M+2% | −$1.1M−74% | −$1.6M+11% | −$382K−79% | −$316.6K−98% | −$86.3K−92% | −$485.8K−69% | −$904.7K+137% | −$685.8K+117% | −$286.3K+232% | −$800.8K+65% | −$1.1M+25% | |
| Interest expense | n/a | −$418−99% | −$18.4K | −$12.7K | n/a | $11.4K | $7.6K | $9.4K | n/a | n/a | n/a | n/a |
| Pre-tax income | −$15.9M+9% | −$996.5K−75% | −$3M+125% | $459.7K | −$152.8K−99% | $15.1K | −$480.8K−84% | −$895.3K | −$680K+345% | −$283.1K | −$798K+66% | −$1.1M+26% |
| $0 | $0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$15.9M+9% | −$996.5K−75% | −$3M+125% | $459.7K | −$152.8K−99% | $15.1K | −$480.8K−84% | −$895.3K | −$680K+345% | −$283.1K | −$798K+66% | −$1.1M+26% |
| −$132.64+44% | n/a | −$10.80−22% | −$1.20−87% | −$1.44−99% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| 127.2K−25% | n/a | 370.1K+120% | 449.1K+51% | 818.5K+544% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating income: 3 periods, Q1 FY18 to Q3 FY18: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY18 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY18 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q3 FY24: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Consumer Defensive nearest cbdMD's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| YCBDcbdMD | $4.1M | n/m | 112× | 0.2× | +10% | −13.8% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| JVACoffee | $25.6M | 5.4× | 23.0× | 0.3× | +8% | 4.9% | |
| RAVERave Restaurant | $31.3M | 10.5× | 13.8× | 2.4× | +7% | 22.3% | |
| AXILAxil Brands | $37.7M | 16.2× | 34.4× | 1.3× | +10% | 9.3% | |
| Peer median | $28.4M | 7.9× | 18.4× | 0.8× | +8% | 8.9% |
More on cbdMD
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
Valuation data, not investment advice. Prices as of .